Grail reports Q2 EPS ($3.18), consensus ($3.56)

Reports Q2 revenue $35.5M, consensus $36.9M. Cash, cash equivalents, restricted cash and short-term marketable securities totaled $606.1M as of June 30. “We are pleased with Galleri’s growing uptake in the U.S., with more than 45,000 Galleri tests sold in the second quarter, as we continue to drive provider and patient awareness of the MCED opportunity and Galleri’s ability to detect cancer earlier, when it is more amenable to treatment,” said Bob Ragusa, Chief Executive Officer at GRAIL (GRAL). “Our registrational trials in large, intended use populations in the U.S. and U.K. are beginning to read out, and following very promising top-line performance and safety results from the PATHFINDER 2 study in the U.S., we plan to submit detailed results for presentation at the European Society for Medical Oncology Congress 2025 in October.”